Clinical Trial

A Phase I Study of CFT8919 in Patients With Advanced NSCLC

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated December 9, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of CFT8919 capsules in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR mutations. The main questions it aims to answer are: * What is the maximum tolerated dose (MTD) of CFT8919? * Does CFT8919 demonstrate antitumor activity in these patients? Participants will: * Take CFT8919 capsules at different doses. * Undergo regular assessments for safety, pharmacokinetics, and tumor response. Researchers will compare different dose levels to determine the best balance between safety and efficacy.
Trial Details
NCT Number NCT06641609
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Non-Small Cell Lung Cancer With EGFR Mutation
Enrollment 166 participants
Start Date 2024-12-13
Primary Completion 2025-12-09 (estimated)
Study Completion 2026-04-03 (estimated)
Updated on ClinicalTrials.gov 2024-10-15